<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00188994</url>
  </required_header>
  <id_info>
    <org_study_id>98-E089</org_study_id>
    <secondary_id>CIHR Grant No. HSF NA4189</secondary_id>
    <nct_id>NCT00188994</nct_id>
  </id_info>
  <brief_title>Insulin Cardioplegia for Poor Left Ventricular Function</brief_title>
  <official_title>Insulin Cardioplegia Trial for Poor Left Ventricular Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <brief_summary>
    <textblock>
      The purpose of this investigation is to develop a means to improve the recovery of cardiac
      metabolism and ventricular function following coronary artery bypass surgery (CABG) in
      patients with poor preoperative ventricular function (e.g. ejection fraction &lt;40%).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis

      Insulin added to blood cardioplegia will improve the results of Coronary Artery Bypass Graft
      by reducing the incidence of low output syndrome (i.e., the requirement for inotropic or
      balloon pump assistance) in patients with a preoperative ejection fraction &lt;40%.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 1999</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Low Output Syndrome</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Troponin I Release</measure>
  </secondary_outcome>
  <enrollment>800</enrollment>
  <condition>Left Ventricular Dysfunction</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Cardioplegia</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has been referred for isolated coronary bypass surgery.

          -  LV grade 3 or 4, LVEF &lt;40% by angio, echo, RNA.

        Exclusion Criteria:

          -  Patient is undergoing reoperative surgery (i.e., has had any previous cardiac surgery)

          -  Surgeon has planned another procedure in addition to coronary bypass surgery (e.g.,
             valve repair, replacement, ascending aorta repair or replacement, left ventricular
             aneurysm resection, repair of congenital defect, carotid surgery, repair of abdominal
             aortic aneurysm).

          -  Patient is scheduled for minimally invasive surgery.

          -  More recent assessment of LV function with LV grade 1 0r 2, LVEF&gt;40%.

          -  5 or 6 days post MI.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terrence M. Yau</last_name>
    <role>Principal Investigator</role>
    <affiliation>21st Century Cardiac Surgical Society, Council on Cardiovascular and Thoracic Surgery (American Heart Association), Canadian Cardiovascular Society, Royal College of Physicians and Surgeons, Institute of Medical Sciences (University of Toronto)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Chet Jabier-Nacario, BScN</last_name>
    <phone>416-340-4800</phone>
    <phone_ext>8435</phone_ext>
    <email>chet.nacario@uhn.on.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chet Jabier-Nacario, BScN</last_name>
      <phone>416-340-4800</phone>
      <phone_ext>8435</phone_ext>
      <email>chet.nacario@uhn.on.ca</email>
    </contact>
    <investigator>
      <last_name>Terrence M. Yau, MD, FRCS(C)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>1. Yau,TM, Fedak PWM, Weisel RD, Teng C, Ivanov J. Predictors of operative risk for coronary bypass operations in patients with left ventricular dysfunction. J Thorac Cardiovasc Surg 1999; 118:1006-1013. 2. RaoV, Ivanov J, Weisel RD, Ikonomidis JS, Christakis GT, David TE. Predictors of low cardiac output syndrome after coronary artery bypass. J Thorac Cardiovasc Surg 1996; 112:38-51. 3. Yau TM, Weisel RD, Mickle DAG, et al: Optimal delivery of blood cardioplegia. Circulation 1991; 84 (SAuppl II):II-380-388. 4. Yau TM, Weisel RD, Mickle DAG, et al: Alternative techniques of cardioplegia. Circulation 1992; 86(Suppl II):II-377-384. 5. Yau TM, Ikonomidis JS, Weisel RD, et al: Which techniques of cardioplegia prevent ischemia? Ann Thorac Surg 1993; 56:1020-1028. 6. Yau TM, Ikonomiodis JS, Weisel RD, et al: Ventricular function after normothermic versus hypothermic cardioplegia. J Thorac Cardiovasc Surg 1993; 105:883-844. 7. Rao V, Merante F, Weisel RD, Shirai T, Ikonomidis JS, Cohen G, Tumiati LC, Shiono N, Li RK, Mickle DAG, Robinson BH. Insulin stimulates pyruvate dehydrogenase and protects human ventricular cardiomyocytes from simulated ischemia. J Thorac Cardiovasc 1998; 116:485-94. 8. Rao V, Borger MA, Weisel RD, Ivanov J, Christakis GT, Cohen G, Yau TM,. Insulin cardioplegia for elective coronary bypass surgery. J Thorac Cardiovasc Surg 2000; 119: 1176-1184. 9. Yau TM, Mickle DAG, Weisel RD: Myocardial free radical reperfusion injury during cardiac surgery, in Kron IL, Mavroudis C (eds): Frontiers in cardiovascular surgical research: State of Art Reviews: Cardiac Surgery. Hanley &amp; Belfus, 1990; 703-712. 10. Christakis GT, Weisel RD, Fremes SE, Ivanov J, David TE, Goldman BS, Salerno TA and the Cardiovascular Surgeons of the University of Toronto, Coronary Artery bypass grafting in patients with poor ventricular function. J Thorac Cardiovasc Surg 1992; 103:1083-1092.</citation>
  </reference>
  <verification_date>July 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>December 28, 2005</last_update_submitted>
  <last_update_submitted_qc>December 28, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2005</last_update_posted>
  <keyword>Myocardial Protection</keyword>
  <keyword>Myocardial Metabolism</keyword>
  <keyword>Ventricular Function</keyword>
  <keyword>Cardiovascular Disease</keyword>
  <keyword>Cardioplegic Additives</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

